News

CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye). CEQUA provides the highest FDA-approved concentration of cyclosporine A (CsA) and is the first

Under the deal, the partnership will carry out research and development activities for the advancement of mRNA-based flu vaccines. BioNTech co-founder and CEO Dr Ugur Sahin said: “Today’s

This vaccine widely targets all major HIV strains and the potential to enhance the capacity of the immune system to eliminate or provide life-long control of HIV. This

BO is a progressive inflammatory condition resulting in airflow obstruction and loss of function in the lung and is considered a form of chronic rejection. There are no

Based in Vienna, Austria, Haplogen is a biotechnology company focused on developing therapeutic substances for the treatment and prevention of infection by the common cold virus. The multi-year

In July 2016, Judge William Alsup of the U.S. District Court, Northern District of California, granted a Motion to Dismiss sought by Gilead in the case [Case #

Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases, and to help ensure people have access to

Ankylosing spondylitis is a painful and progressive type of arthritis, in which some or all of the joints and bones of the spine fuse together. The disease is

The Series C round was led by Deerfield Management while RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors and others made significant new investments in the gene therapy